Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Brazil passes anti-gang law allowing seized crypto to fund security forces - 2'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- 3The Best Internet based Retailers for Style and Frill
- 4Woman shocked to welcome baby after experiencing stomach pain on Christmas
- 5Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- 'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- Zelensky sees new Russian attack threat from Belarus
- How does Spotify Wrapped calculate your listening age? What your number says about you.
- ‘Democratizing space’ is more than just adding new players – it comes with questions around sustainability and sovereignty
- My Dad Can't Travel Like He Used to, but Slowing Down Doesn't Mean Stopping
- Reveal Less popular Authentic Realities You Didn't Learn in School
- Beyond oil: The crucial exports blocked by Hormuz closure
- Make your choice for a definitive Christmas place to get-away!
- EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
